Hormone pellet therapy marketing: approval status, compounded pellets and safety claims

Hormone pellets are small implants placed under the skin, usually in the hip or buttock area, that release a hormone over months. Clinics offer them to men for low testosterone and, in hormone, menopause and wellness practices, to women for menopause symptoms, energy, libido and weight. The marketing tends to stress convenience (“one visit every few months”), “natural” or “bioidentical” hormones and steady levels. Several of those claims run straight into what the federal record says about pellets.

This guide covers which pellet products FDA has approved and for what, what that label says about risks, how compounded pellets differ, what the 2020 National Academies report found about compounded hormones and pellets in particular, and how FDA and FTC claim rules apply to a pellet service page. For the wider fields, see our guides to menopause clinic marketing and TRT clinic marketing.

The short version

• One approved pellet, for men with diagnosed hypogonadism. When we searched Drugs@FDA through openFDA on November 1, 2026, the only prescription pellet for implantation was a 75 mg testosterone pellet, approved for testosterone replacement in males with primary or hypogonadotropic hypogonadism and for selected cases of delayed puberty. We found no approved estradiol pellet.
• Its label limits the claims. It says safety and efficacy in men with age-related hypogonadism have not been established, asks for a confirmed diagnosis from two morning blood tests, and lists implant site infection, pellet extrusion, blood clots, blood pressure increases and other risks.
• Pellets for women are compounded. Compounded drugs are not FDA-approved, and FDA lists calling them approved, generic or the same as an approved drug as false or misleading.
• NASEM flagged pellets. The 2020 report recommended that all compounded bioidentical hormone pellets be considered as candidates for FDA’s Difficult to Compound List, and that patients be told compounded preparations are not FDA-approved.
• FTC rules apply. Claims about energy, weight, libido, mood, bone or heart health, or “safer and more natural” hormones need competent and reliable scientific evidence, and that includes testimonials.

What FDA has approved

Drugs@FDA, searched through openFDA (data last updated October 30, 2026), returned three products with a pellet dosage form. One is an oral capsule. One is an implantable hormone pellet that is discontinued and is not a sex hormone. The third is a testosterone pellet, 75 mg, for subcutaneous implantation, listed as a prescription product with an original approval date of July 13, 1972. We found no approved pellet that contains estradiol or any other estrogen.

That matters for marketing in two ways. First, a men’s testosterone pellet can be an FDA-approved product, but only when the clinic actually uses that product. Second, an estradiol pellet, or a testosterone pellet compounded in a dose for women, is not an approved product. A page that says “FDA-approved hormone pellets” next to a women’s menopause offer is describing something that, as far as the FDA record shows, does not exist.

What the approved label says

The prescribing information for the approved pellet (effective July 17, 2025, as listed in openFDA) sets the limits a men’s pellet page should stay inside:

• Indication. Replacement therapy in males with conditions associated with a deficiency or absence of testosterone: primary hypogonadism and hypogonadotropic hypogonadism, each from named causes, plus carefully selected males with clearly delayed puberty.
• Aging. The label states that safety and efficacy in men with “age-related hypogonadism” (also called late-onset hypogonadism) have not been established.
• Diagnosis first. Before starting, the label says to confirm hypogonadism with serum testosterone measured in the morning on at least two separate days, both below the normal range.
• Implant risks. Post-marketing cases associate pellet insertion with implant site infection (cellulitis and abscess) and pellet extrusion. The label says most reported cases occurred within the first month and may need further treatment.
• Other risks. The warnings cover venous blood clots, blood pressure increases that can raise cardiovascular risk over time, edema in patients with heart, kidney or liver disease, and abuse. The label says studies have been inconclusive on major cardiovascular events and that some studies, but not all, have reported an increased risk, and that patients should be told about this possible risk.
• Controlled substance. The label states testosterone is a Schedule III controlled substance, consistent with the anabolic steroid listing in 21 CFR 1308.13(f).

The label also lists adverse reactions reported in women, including hirsutism, virilization, deepening of the voice, clitoral enlargement, breast atrophy, male-pattern baldness and menstrual irregularities. A clinic that offers testosterone pellets to women should not borrow the men’s product’s approval in its ads, and should be ready to describe these risks plainly.

For a men’s clinic, this rules out “pellets reverse male aging,” “for any man over 40 who feels tired” and “no blood work needed.” Our TRT clinic marketing guide covers telehealth prescribing and the ad platform rules for testosterone.

Compounded pellets: what you can and cannot say

Because we found no approved estrogen pellet, an estradiol pellet, and any testosterone pellet other than the approved product, is made by a compounding pharmacy or an outsourcing facility. Under 21 USC 353a, a drug compounded for an identified individual patient based on a valid prescription can be exempt from FDA approval requirements when the law’s conditions are met. Being exempt from approval is not the same as being approved. FDA’s page on the risks of compounded drugs (content current as of June 22, 2026) says compounded drugs are not FDA-approved, so the agency does not review their safety, effectiveness or quality before they are marketed.

FDA’s page on promoting compounded drugs (content current as of June 15, 2026) lists claims it considers false or misleading. Applied to pellets, do not:

• call a compounded pellet FDA-approved, or say it has been evaluated by FDA for safety and effectiveness;
• call it a generic version of, or the same as, an FDA-approved hormone product;
• say it is clinically proven to produce the same result as an approved product;
• say it comes from an FDA-approved or FDA-licensed pharmacy or outsourcing facility, because FDA does not approve or license any facility.

21 USC 353a(b)(3)(A) also bars compounding a drug product that FDA has identified by regulation as presenting demonstrable difficulties for compounding that reasonably demonstrate an adverse effect on safety or effectiveness. That is the list NASEM pointed to for pellets, below. Our compounding pharmacy marketing guide covers the 503A and 503B rules in more detail.

What the National Academies found

In 2018 FDA asked the National Academies of Sciences, Engineering, and Medicine (NASEM) to review the evidence on compounded bioidentical hormone therapy. FDA’s page on the study says NASEM delivered its analysis on July 1, 2020 and found a lack of rigorous evidence of safety and effectiveness from well-designed or properly controlled clinical studies, with information coming mostly from low quality data such as anecdotal claims, patient reports and prescriber testimonies. FDA’s page says NASEM concluded that the wide-spread use of these products poses a public health concern.

The report’s Summary chapter speaks directly to marketing and to pellets:

• It says there is a dearth of evidence to support many of the marketed claims for the clinical utility of compounded bioidentical hormones as a treatment of menopausal and male hypogonadism symptoms.
• It describes patient beliefs that these hormones are “natural” and safer than FDA-approved products, and says those motivations were often influenced by marketing strategies used by advocates and suppliers of compounded medications.
• Recommendation 1 says prescribers should restrict compounded hormones to a documented allergy to an ingredient of an approved product or a documented need for a different dosage form, that patient preference alone should not decide, and that prescribers and compounding pharmacists should inform patients that compounded preparations are not FDA-approved.
• Recommendation 2 says the Pharmacy Compounding Advisory Committee should consider all compounded bioidentical hormone preparations in pellet dosage form as candidates for FDA’s Difficult to Compound List.

A recommendation is not a rule. FDA’s compounding regulations in 21 CFR part 216 (eCFR version as of October 29, 2026) contain no list of drug products that are demonstrably difficult to compound, so pellets are not on a final list. But the report was commissioned by FDA to review the evidence on these products, so a page that calls compounded pellets proven, safer or more natural than approved hormones is making the exact claims the report says lack evidence.

What the FTC requires

Section 5 of the FTC Act declares unfair or deceptive acts or practices unlawful (15 USC 45(a)), and section 12 makes it unlawful to disseminate a false advertisement to induce the purchase of drugs, devices or services (15 USC 52). Under 15 USC 55(a)(1), whether an ad is misleading includes what it fails to reveal about the consequences of using the product as the ad describes.

The FTC Health Products Compliance Guidance says health claims need competent and reliable scientific evidence and that the agency judges an ad by its net impression, including implied claims. Pellet ads commonly claim, or imply:

• “Bioidentical, so safer and more natural.” NASEM found no rigorous evidence that compounded hormones are safer, and “natural” does not tell a patient anything about risk.
• “Steady hormone levels with no peaks and valleys.” That is a pharmacokinetic claim about your specific compounded product, and NASEM recommended more bioavailability information for sterile preparations including pellets precisely because it is lacking.
• Weight loss, energy, sleep, mood, memory, libido, bone protection or heart protection. Each is a health or disease claim that needs evidence for the product, dose and patient group you are advertising.
• “No side effects” or “just a tiny pellet.” The approved label lists infection, extrusion, clots and blood pressure effects, and omitting known risks can itself mislead under 15 USC 55(a)(1).

Softer wording does not change the takeaway. “Many patients feel like themselves again” still tells the reader the treatment works, and the FTC looks at what the reader understands.

Testimonials, before-and-after stories and pricing

Pellet clinics rely heavily on patient stories. Under 16 CFR 255.2(a), an advertiser needs substantiation for what a consumer endorsement conveys, as if it had made the claim itself, so “pellets gave me my life back and I lost 20 pounds” carries a claim the clinic must support. Under 16 CFR 255.2(b), an endorsement about a central attribute is likely to be read as typical unless the ad clearly discloses the generally expected results. See our guide to patient testimonials and before-and-after photos.

For pricing, state what an insertion includes (lab work, the visit, the pellets), how often re-insertion is typical under your protocol, and refund terms. A “was” price needs a price you actually charged in good faith for a reasonably substantial period (16 CFR 233.1(a)). Membership plans should say what happens if the patient stops or a pellet extrudes. See advertising cash prices.

What you can say

• What the procedure is: a small incision under local anesthetic, placement of the pellet under the skin, and aftercare instructions.
• Whether you use an FDA-approved product or a compounded preparation, stated plainly, and for compounded pellets, that they are not FDA-approved.
• Who evaluates patients, what lab tests you run before and during treatment, and how dosing decisions are made.
• Known risks in plain words, starting with those on the approved label: implant site infection, pellet extrusion, blood clots and blood pressure changes, and for women, the androgen effects listed above.
• That a pellet cannot be easily adjusted or removed once placed, if that is true under your protocol, and what the alternatives are.
• Price, what it includes, and how often patients usually return.

Leave out: “FDA-approved” for any compounded pellet, “safer,” “natural” or “no side effects,” anti-aging promises, weight, heart, bone or brain claims, guarantees about how long a pellet lasts, and any claim that pellets are the same as an approved hormone product.

An example (made up)

This illustration is invented. A wellness clinic’s page says: “FDA-approved bioidentical hormone pellets for men and women. All natural, safer than synthetic HRT, with no peaks and valleys. Lose weight, sleep better and protect your heart. One quick visit every 3 to 4 months. Was $650, now $399!”

Fixes: “FDA-approved” comes off for women’s pellets, because we found no approved estrogen pellet and compounded products are not approved; it can stay for men only if the clinic uses the approved product, for the approved use. “All natural, safer than synthetic HRT” comes off, because NASEM found no rigorous evidence of that and FDA lists equivalence claims as misleading. “No peaks and valleys” comes off unless the clinic has product-specific evidence. Weight, sleep and heart claims come off. The page should add who is evaluated and how, the lab tests, the label’s risks and a line that compounded pellets are not FDA-approved. The “was $650” stays only if patients actually paid it for a reasonable period.

Checklist

• Know which product you insert: the approved testosterone pellet or a compounded preparation (Drugs@FDA).
• No “FDA-approved” wording for compounded pellets, and no generic, same-as or facility-approval claims (FDA promoting compounded drugs page).
• Men’s pages match the approved indication: diagnosed hypogonadism, not age-related low energy (approved label).
• Diagnosis and lab monitoring described accurately.
• Implant site infection, extrusion, clots, blood pressure and women’s androgen effects stated where the service is sold (15 USC 55(a)(1)).
• No safer, natural, steady-level, weight, heart, bone or brain claims without competent and reliable scientific evidence (15 USC 45, 52; FTC guidance).
• Testimonials do not say what the clinic could not say (16 CFR 255.2).
• Prices, inclusions and former prices are real and clear (16 CFR 233.1).
• State rules on who prescribes and inserts pellets checked with counsel.
• Ads, social posts, booking pages and phone scripts match the website.

How we help

We build service pages for hormone, menopause, men’s health and wellness practices with claims checked against the sources above: website design, healthcare SEO for treatment searches, and lead generation campaigns that describe treatments without approval, safety or anti-aging overclaims. We do not decide whether a treatment is safe or effective, we do not give legal opinions, and we are not a law firm. Related guides: prescription treatment advertising, longevity clinic marketing, functional medicine practice marketing and peptide therapy clinic marketing.

Sources

• openFDA Drugs@FDA data (last updated October 30, 2026)
• openFDA drug labeling data (approved testosterone pellet label effective July 17, 2025)
• National Academies: The Clinical Utility of Compounded Bioidentical Hormone Therapy (2020), Summary
• FDA: NASEM study on compounded “bioidentical” hormone therapy
• FDA: What to Know When Promoting Compounded Drugs (content current as of June 15, 2026)
• FDA: Understanding the Risks of Compounded Drugs (content current as of June 22, 2026)
• 21 USC 353a: Pharmacy compounding
• 21 CFR part 216: Human drug compounding
• 21 CFR 1308.13: Schedule III
• 15 USC 45: Unfair methods of competition unlawful
• 15 USC 52: Dissemination of false advertisements
• 15 USC 55: Additional definitions
• FTC: Health Products Compliance Guidance (December 2022)
• 16 CFR 255.2: Consumer endorsements
• 16 CFR 233.1: Former price comparisons

More in Cash-pay, aesthetic and wellness care